Automated Trading Based on Stock Prediction Algorithm: Returns up to 278.96% in 1 Year

Best Share To Buy Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 1 Year (05/25/2017 - 05/25/2018)
I Know First Average: 93.35%

Read The Full Forecast

Automated Trading

Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility

Winning Stock Forecast: Nektar Therapeutics (NASDAQ: NKTR) Up 340.47% In 1-Year As Forecasted Amid Its Stock Volatility

[Source: Live Trading News, May 23, 2018]

“Already, this year to-date, we have achieved multiple successes with our pipeline of Nektar invented medicines across three therapeutic areas, immuno-oncology, immunology and pain. In the area of chronic pain, we will submit the NDA for NKTR-181 to the FDA this month”

— Howard Robin – President and CEO of Nektar Therapeutics

Summary

  • Over the past year  NKTR went up 340.47%
  • They are one of the most robust growers investors more so during the past 12 months – due to many catalysts powering the firm.
  • Nektar recently commenced the phase 1B study of NKTR-358 for systemic lupus erythematosus.
  • If the mentioned drug can post robust clinical outcomes as prognosticated, it can cut into the $45.5B autoimmune diseases market to deliver significantly more upsides for Nektar.

Over the past year, from May 21 2017 through May 21 2018, NKTR produced a whopping 340.47% return to investors. Nektar Therapeutics is one of the most robust growers investors have encountered in all years of analytical research, especially during the past 12 months: this is due to many catalysts powering the firm. One, the company obtained the $1.85 billion collaborative deal with Bristol-Myers Squibb on February 14, 2018 for the investigation of NKTR-214 in 20 different cancer diagnoses. Approximately two months afterwards (on April 12), the company announced the dosing of the first patient in the REVEAL trial that created substantial value to their investing thesis. Nevertheless, all recent developments are minuscule compared to what will come. In this article, we’ll clarify the latest catalysts that gave Nektar substantial upside in the long haul, and will continue to do so in the coming months.

Read More

Market Predictions Based on Big Data: Returns up to 340.47% in 1 Year

Best Share To Buy Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 1 Year (05/21/2017 - 05/21/2018)
I Know First Average: 90.56%

Read The Full Forecast

Market Predictions

Quant Trading Based on Big Data Analytics : Returns up to 336.54% in 1 Year

Best Share To Buy Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 1 Year (05/19/2017 - 05/19/2018)
I Know First Average: 90.91%

Read The Full Forecast

Quant Trading

Algorithmic Trading Strategy Based on Genetic Algorithms: Returns up to 333.11% in 1 Year

Best Share To Buy Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 1 Year (05/16/2017 - 05/16/2018)
I Know First Average: 73.16%

Read The Full Forecast

Algorithmic Trading Strategy

Top Rated Stocks Based on Big Data: Returns up to 310.60% in 1 Year

Best Share To Buy Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 1 Year (05/14/2017 - 05/14/2018)
I Know First Average: 69.89%

Read The Full Forecast

Top Rated Stocks

Stock Market Forecasting Based on Stock Algorithm: Returns up to 309.27% in 1 Year

Best Share To Buy Package Name: High Volume Stocks
Recommended Positions: Long
Forecast Length: 1 Year (05/12/2017 - 05/12/2018)
I Know First Average: 70.01%

Read The Full Forecast

Stock Market Forecasting
Pages:1234567...15»